↓ Skip to main content

Granzyme B-inhibitor serpina3n induces neuroprotection in vitro and in vivo

Overview of attention for article published in Journal of Neuroinflammation, September 2015
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#37 of 2,953)
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
10 news outlets
blogs
2 blogs
twitter
5 X users
patent
1 patent

Citations

dimensions_citation
61 Dimensions

Readers on

mendeley
78 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Granzyme B-inhibitor serpina3n induces neuroprotection in vitro and in vivo
Published in
Journal of Neuroinflammation, September 2015
DOI 10.1186/s12974-015-0376-7
Pubmed ID
Authors

Yohannes Haile, Katia Carmine-Simmen, Camille Olechowski, Bradley Kerr, R. Chris Bleackley, Fabrizio Giuliani

Abstract

Multiple sclerosis (MS) is an autoimmune inflammatory and neurodegenerative disease of the central nervous system (CNS). It is widely accepted that inflammatory cells play major roles in the pathogenesis of MS, possibly through the use of serine protease granzyme B (GrB) secreted from the granules of cytotoxic T cells. We have previously identified GrB as a mediator of axonal injury and neuronal death. In this study, our goal was to evaluate the effect of GrB inhibition in the human system in vitro, and in vivo in EAE using the newly isolated GrB-inhibitor serpina3n. We used a well-established in vitro model of neuroinflammation characterized by a co-culture system between human fetal neurons and lymphocytes. In vivo, we induced EAE in 10- to 12-week-old female C57/BL6 mice and treated them intravenously with serpina3n. In the in vitro co-culture system, pre-treatment of lymphocytes with serpina3n prevented neuronal killing and cleavage of the cytoskeletal protein alpha-tubulin, a known substrate for GrB. Moreover, in EAE, 50 μg serpina3n substantially reduced the severity of the disease. This dose was administered intravenously twice at days 7 and 20 post EAE induction. serpina3n treatment reduced axonal and neuronal injury compared to the vehicle-treated control group and maintained the integrity of myelin. Interestingly, serpina3n treatment did not seem to reduce the infiltration of immune cells (CD4(+) and CD8(+) T cells) into the CNS. Our data suggest further studies on serpina3n as a potentially novel therapeutic strategy for the treatment of inflammatory-mediated neurodegenerative diseases such as MS.

X Demographics

X Demographics

The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 78 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 2 3%
Unknown 76 97%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 17 22%
Researcher 14 18%
Student > Master 14 18%
Student > Bachelor 11 14%
Other 4 5%
Other 5 6%
Unknown 13 17%
Readers by discipline Count As %
Agricultural and Biological Sciences 17 22%
Neuroscience 13 17%
Biochemistry, Genetics and Molecular Biology 10 13%
Immunology and Microbiology 9 12%
Medicine and Dentistry 7 9%
Other 6 8%
Unknown 16 21%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 85. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 March 2022.
All research outputs
#501,970
of 25,396,120 outputs
Outputs from Journal of Neuroinflammation
#37
of 2,953 outputs
Outputs of similar age
#6,467
of 277,653 outputs
Outputs of similar age from Journal of Neuroinflammation
#1
of 47 outputs
Altmetric has tracked 25,396,120 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,953 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.7. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 277,653 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 47 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.